Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $56.04, down -0.14%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RYTM shares have gain 1.43% over the last week, with a monthly amount drifted -5.07%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on December 20, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $76. Previously, Guggenheim started tracking the stock with Buy rating on October 21, 2024, and set its price target to $70. On September 18, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $64 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $64 on September 17, 2024. BofA Securities downgraded its rating to a Neutral and reduced its price target to $42 on May 08, 2024. Morgan Stanley upgraded its rating to Overweight for this stock on December 19, 2023, and upped its price target to $55. In a note dated August 01, 2023, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $22 to $27.
Rhythm Pharmaceuticals Inc [RYTM] stock has fluctuated between $35.17 and $68.58 over the past year. Currently, Wall Street analysts expect the stock to reach $64.5 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $56.04 at the most recent close of the market. An investor can expect a potential return of 15.1% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] reported sales of 112.53M for the trailing twelve months, which represents a growth of 47.76%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -2.36%, Pretax Profit Margin comes in at -2.3%, and Net Profit Margin reading is -2.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -3.69 and Total Capital is -1.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.69 points at the first support level, and at 53.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 57.00, and for the 2nd resistance point, it is at 57.95.
Ratios To Look Out For
For context, Rhythm Pharmaceuticals Inc’s Current Ratio is 3.49. As well, the Quick Ratio is 3.34, while the Cash Ratio is 0.49. Considering the valuation of this stock, the price to sales ratio is 30.96, the price to book ratio is 306.98.
Transactions by insiders
Recent insider trading involved Lee Jennifer Kayden, EVP, Head of North America, that happened on Nov 11 ’24 when 66861.0 shares were sold. Chief Technical Officer, Shulman Joseph completed a deal on Nov 11 ’24 to sell 13281.0 shares. Meanwhile, Officer JENNIFER KAYDEN LEE bought 66861.0 shares on Nov 11 ’24.
